News Two more biotechs, Attovia and Braveheart, join the IPO line The steady stream of biotechs aiming to list on the Nasdaq has continued, with Attovia and Braveheart the latest to make their intentions known.
News Dupixent delivers in two skin disease trials Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications f
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.